8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2025
Open accessThe DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“physical activity plays an indispensable role”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [53]
In the citing paper
“Evidence-based dietary management is the cornerstone of T2DM prevention and control, as it can effectively improve glycemic control and even achieve disease remission (2).”
In the citing paper
“Those with obesity who have engaged in some form of calorie or dietary restriction have a higher likelihood of developing nutritional deficiencies [53,98,99,130,131]”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [53]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15268-3 · Cited by 12,717
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationEffects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Self-citation2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Self-citationBariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Research works printed but not linked: 2
- Steven, 2016, Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes Care 2016;39:808–815, Diabetes Care, 41, 1321
- American Medical Association . Person-First Language for Obesity H-440.821. Accessed 21 August 2024. Available from https://policysearch.ama-assn.org/policyfinder/detail/obesity?uri=%2FAMADoc%2FHOD.xml-H-440.821.xml
Cited by
Items 101–200 of 269
Johansen, M. Y., Durrer, C. G., Pilmark, N. S., Legaard, G. E., Karstoft, K., Hansen, K. B., MacDonald, C., Almdal, T., Bjørner, J. B., Albrechtsen, N. J. W., et al. (2025) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2025.101059 · Cited by 3
Lee, Y. A., Huang, Y., Dai, H., Yuce, T. K., Shah, V. N., Bian, J., & Guo, J. S. (2025) · medRxiv · doi:10.1101/2025.11.10.25339913 · Cited by 3
Kushwaha, S., Khanna, P., Bhadada, S. K., Sagar, V., Gupta, P. K., Thakur, J. S., Gupta, M., & Srivastava, R. (2025) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2025.101470 · Cited by 2
GLP-1 medications versus surgery and balloon: evaluating cost-benefit in weight loss
Salazar, C. I. V., Lopez, S. Z. K., Rios, C. R., & Coutiño, L. F. G. (2025) · International Surgery Journal · doi:10.18203/2349-2902.isj20251200 · Cited by 2
Recovery time of diabetic ketoacidosis in Africa: Systematic review and meta-analysis
Lidetu, T., Birhanu, S., Asgai, A. S., Derse, T. K., Abinew, Y., Abebe, M. T., Kidie, D. M., Fetene, J. C., Adane, B., Wudu, T. K., et al. (2025) · Metabolism Open · doi:10.1016/j.metop.2025.100370 · Cited by 2
Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment
Bensignor, M. O., Hsia, D. S., Name, M. A. V., Jastreboff, A. M., & Ryder, J. R. (2025) · Diabetes Care · doi:10.2337/dci25-0031 · Cited by 2
2024 Taiwan clinical practice guideline for diabetic kidney disease – an executive summary
Su, S., Chang, T.-C., Chiu, Y., Chu, C., Hsu, Y., Kuo, C., Lee, C., Lin, M., Lin, C., Lin, Y.-F., et al. (2025) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2025.08.020 · Cited by 3
Kushner, P. R., Campos, C., King, A., Kruger, D. F., & Morales, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0037 · Cited by 3
“Weight loss at this level is important in those with type 2 diabetes and overweight or obesity because it provides a multitude of benefits, such as improved metabolism, glycemic con-trol, and cardiovascular outcomes, including blood pressure, and reduced mortality (3,5,16).”
Lisco, G., Tullio, A. D., Disoteo, O., Armigliato, M., Guastamacchia, E., Marucci, S., Pergola, G. D., Papini, E., Chianelli, M., Frasoldati, A., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70073 · Cited by 2
Vich-Pérez, P., Taulero-Escalera, B., Regueiro-Toribio, P., Checa, I. P., García-Espinosa, V., Villanova-Cuadra, L., Sevilla-Machuca, I., Timoner-García, J., Martínez-Grandmontagne, M., Abós-Pueyo, T., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196770 · Cited by 2
“Severe obesity compounds diabetes-related complications and limits physical functioning, worsening patient-reported health [35].”
Lin, J., Liu, S., Gao, L., Guo, X., & Hu, X. (2025) · BMC Public Health · doi:10.1186/s12889-025-24790-x · Cited by 4
“Therefore, when developing dietary intervention programs for prediabetic patients, Healthcare professionals should prioritize weight loss strategies in addition to dietary modifications, aiming for at least a 3~ 7% reduction in baseline body weight [60].”
Hisada, H., Ikeuchi, K., Tsuji, Y., Yamamichi, N., Kakushima, N., Okushin, K., Yakabi, S., Takeuchi, C., Ohki, D., Mizutani, H., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70194 · Cited by 3
“1,2 In the United States, GLP-1RAs are now widely prescribed for the management of diabetes mellitus and obesity.”
KOVIL, R. R., Shah, T., Tanna, S., Negalur, V. B., PATANGE, S. A., Sanghvi, A., Manoria, P., TIWASKAR, M. H., PADHYE, D. A., Sowani, A., et al. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_22_25 · Cited by 2
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2025rbgo200 · Cited by 2
Pedroso, I., Saravanan, S. K., Kumbhare, S. V., Sharma, G., Almonacid, D. E., & Sinha, R. (2025) · Healthcare · doi:10.3390/healthcare13233147 · Cited by 2
“…of the digital health intervention being evaluated and for which there exists evidence of being responsive to dietary interventions and significantly contribute to high expenditure in employer-sponsored plans: obesity [4,62,63,65,70,71], digestive health [31,72] and mental health [66,67,73–75].”
Jain, A., Kristensen, P. N., Wasehuus, R. S., Kruse, C., & Nørtoft, E. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70350 · Cited by 3
Piona, C. A., Aiello, E. M., Mancioppi, V., Caiazza, E., Olivieri, F., Passanisi, S., Lombardo, F., Mastropasqua, C., Giannini, C., Riccardi, G., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251407959 · Cited by 2
Savvidou, S., Augousti-Varela, E., Damianakou, A., Chalkias, M., & Stergiou, I. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1177/15578518251409025 · Cited by 2
Features of the POUNDS Lost Trial: On the Road to Personalized Nutrition
Heianza, Y., Bray, G. A., Sacks, F. M., & Qi, L. (2026) · Springer eBooks · doi:10.1007/978-3-031-32047-7_155-1 · Cited by 1
Banerjee, M., & Dasgupta, S. (2026) · Cureus · doi:10.7759/cureus.102358 · Cited by 3
Surgical and interventional approaches for the treatment of obesity
Gant, L., & Myerson, M. L. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.003 · Cited by 2
Nowak, M. Z., Núñez, L. M., Pagliaro, T., Robson, M. D., Duncker, C. M., Kaplan, L. M., Heymsfield, S., Thomaides-Brears, H. B., Bell, J. D., & Thomas, E. L. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02037-y · Cited by 3
Beyond the Scale: Setting Goals for Outcomes Beyond Weight in Evidence-based Obesity Treatment
Schumacher, L. M., Hayes, J. F., Olson, K. L., Flanagan, S. P., Wohler, D., & Darling, K. E. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00706-7 · Cited by 2
“…many of the same factors as changes to the definition of obesity, as well as the expanded range of treatment options (e.g., newer obesity management medica - tions [OMMs]), which offer more opportunities to tailor treat - ment to patients’ individual circumstances and preferences [14 , 17 , 18 ].”
Wyss, F. S., Ullauri, V. E., Lara-Terán, J. J., Arteaga-Arellano, A., Martín, C. G., López-Santi, R., Pérez, G., Madrigal, C. A., Ger, M., Piskorz, D. L., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02157-5 · Cited by 3
“Obesity is not only a risk factor for the development of diabetes but also a key pathophysiological driver of the disease itself, other cardiovascular risk factors, and ultimately cardiovascular and kidney disease [61].”
Arterburn, D. E., Curtis, L. H., Toh, S., Bradley, M. C., D’Alessio, D., Duchovny, N., Hines, D. W., Narain, K. D. C., Parekh, A., Skinner, A., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05468 · Cited by 3
González‐Vidal, T., Rivas‐Otero, D., Lambert, C., Ares, J., Delgado, E., & Torre, E. L. M. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501577 · Cited by 3
Sample, J. W., Cottam, D. R., Lind, R. P., Surve, A., Ghanem, M., Medlin, W., Laplante, S. J., Hage, K., Kee, C., Belnap, L. P., et al. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.03.007 · Cited by 2
Bennasar‐Veny, M., Abbate, M., Colom-Rosselló, M., Capitán‐Moyano, L., Hernandez-Bermudez, I. C., Ricci‐Cabello, I., Yáñez, A. M., Fernández, M. E., the ALADIM investigators, Fresneda-Genovard, S., et al. (2025) · Implementation Science · doi:10.1186/s13012-025-01438-3 · Cited by 2
“…strong evidence supporting the effectiveness of lifestyle interventions, and international guidelines recommending screening and referral of individuals with prediabetes [9, 20, 21], implementation of diabetes prevention programs in real-world healthcare practice remains insufficient [22, 23].”
El‐Sehrawy, A. A. M. A., Amirhosseinjaberi, Zandi, E., Yazdi, F., Rafiei, S., Sapaev, I. B., Shayan, S. K., Ali‐Khiavi, P., Salajegheh, P., Shadi, M., et al. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70446 · Cited by 2
Johnson, J., Benzer, J. A., Salvati, L. A., Westerhof, L., & Lepoire, A. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70024 · Cited by 1
Miller, C. K., Young-Hyman, D. L., Wooldridge, J. S., Piatt, G., & Hawkins, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0020 · Cited by 1
Prabhu, K. S., Habeeba, U., Rahman, M. U. A., Perez, M. S., Ramirez, S. A., Khan, B. U., Kuttikrishnan, S., Silang, J. P. B., Kaabi, N. A., Khan, A. Q., et al. (2025) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2025.102088 · Cited by 2
Campbell, J. M. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118413 · Cited by 1
Direct and Indirect Pathways Between Food Insecurity and Glycemic Control in Adults with Diabetes
Walker, R. J., Amjad, R., Campbell, J. A., & Egede, L. E. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09779-x · Cited by 1
Zaman, F., Farhangiyan, Z., Alamdari, M., Moradi, L., & Ashrafi, A. (2025) · Cureus · doi:10.7759/cureus.91245 · Cited by 1
Evaluating Cardio-Protective Molecules by Efficacy Based on Weight Reduction and HbA1c Targets
Salmen, T., Pietroșel, V.-A., Urzica, F.-V., Visan, D.-E., Salmen, B.-M., Cîmpeanu, R.-C., Reurean‐Pintilei, D., Popoviciu, M. S., & Stoian, A. P. (2025) · Biomedicines · doi:10.3390/biomedicines13092306 · Cited by 1
“…recommend various specific approaches to weight loss—from reducing a specific number of calories per day (e.g., 500–750), or a weight loss of 0.5–1 kg per week, or increasing the amount of physical activity per day—they all agree that at least achieving a weight loss of 5% is recommended [27,29].”
InfluentialCheng, J., Yu, H., Gu, Y., Ma, C., Li, C., Pan, Z., & Yuan, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70152 · Cited by 3
“…recommend that bariatric surgery should be considered as a weight and glycemic management approach in T2DM patients with BMI ≥ 30.0 kg/m 2 , 4 and our study further demonstrated that bariatric surgery offered superior benefits in diabetes remission compared to medical management, both in…”
InfluentialGómez, A. M., Chicue, M.-P., Henao, D. C., & Múñoz, Ó. (2025) · Journal of International Medical Research · doi:10.1177/03000605251382375 · Cited by 1
Jang, M. K., Yoon, S., An, J., Kim, J. S., Kim, M., Lee, J. A., Ko, C. S., & Min, S. H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207284 · Cited by 1
“For adults with T2DM, the American Diabetes Association further supports the use of MBS as a weight and glycemic management strategy starting from BMI ≥ 30 kg/m 2 (or ≥ 27.5 kg/m 2 in Asian individuals) in appropriate surgical candidates [11].”
Influentialaf Geijerstam, P., Johansson, E., Fägerstam, S., Wu, J. H. Y., Ghafouri, B., Karlsson, K., Hebib, L., Kastbom, L., Wennberg, P., Hedov, E. G., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-110141 · Cited by 1
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615i · Cited by 2
Chen, D.-A., Pena, R. H., Oldenburg, N. C., Wang, Q., Helgeson, E. S., Yentzer, B., Taddese, A., LaPage, N., Manoogian, E. N. C., Panda, S., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01968-2 · Cited by 1
“The ADA recommends individualizing nutritional approaches rather than prescribing a speci fi c plan or macronutrient composition [3].”
Optimising contraceptive counselling: insights for obesity and bariatric surgery patients
Arroyo, J., Fuentes‐Mendoza, J. M., Concepción‐Zavaleta, M. J., Castillo‐Velásquez, F. G., Velarde-García, D., Aldave, J. E. Q., Urteaga, L. A. C., & Paz‐Ibarra, J. (2026) · The European Journal of Contraception & Reproductive Health Care · doi:10.1080/13625187.2025.2609771 · Cited by 1
“…of treatment or following dose escalations. therefore, a non-oral contraceptive method, such as intrauterine devices, implants, injectables, or barrier methods, is preferred, or a barrier method should be added for at least four weeks after treatment initiation or each dose escalation [77,78].”
Long-term management of body weight and physiological mechanisms of weight regain
Hu, T., & Bao, Y. (2026) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaf062 · Cited by 1
“Evidence-based healthy eating approaches can be selected based on individual preference, metabolic risk profile, and likelihood of long-term adherence (Garvey et al., 2016 ; American Diabetes Association Professional Practice Committee, 2025 ).”
The association of GLP-1 receptor agonists and outcomes following midfoot arthrodesis
Bank, N. C., Lauck, B. J., Dalola, J., Duggan, S. T., Dyke, W. B., & Lalli, T. A. J. (2026) · The Journal of Foot & Ankle Surgery · doi:10.1053/j.jfas.2026.01.011 · Cited by 1
Jabbour, J., Issa, Z. A., Jaafar, T., Jaafari, S. A., Alaaedeen, L., Tabesh, A. A., Horanieh, R., Hammad, N. M., & Chakhtoura, M. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuaf297 · Cited by 1
Abusnana, S., Sabbour, H. M., Afandi, B. O., Farghaly, M., Farooqi, M. H., Hafidh, K., Hassanein, M. M., Jabbar, A., Shehab, A., Kalimat, R., et al. (2026) · Vascular Health and Risk Management · doi:10.2147/vhrm.s579970 · Cited by 1
“46,97 For an individual with dysglycemia and obesity, loss of 3–7% of initial weight is likely to improve a range of cardiometabolic risk factors, while loss of at least 10% of initial weight may improve long-term clinical outcomes.”
Kandalam, S., Benamar, M., Reun, C. L., Rengger, L., Gupta, P., & Nair, S. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01847-7 · Cited by 1
“Moreover, higher weight reduction with IcoSema can improve insulin sensitivity and reduce glycaemia, lowering the need for glucose-lowering medications and improving cardiovascular outcomes in the long term [29–31].”
Yuan, W., He, S., Zang, Y., & Deng, L. (2026) · Scientific Reports · doi:10.1038/s41598-026-40395-9 · Cited by 2
Current management of MASLD in type 2 diabetes
Fernández‐Garibay, V. M., Sarabia-Chao, V., & Chávez-Tapia, N. C. (2026) · HORMONES · doi:10.1007/s42000-026-00763-6 · Cited by 1
Hasnani, D., Chavda, V., Abichandani, V. K., Saboo, B., DESAI, S., PATADIA, V., Vora, F., MORI, B. S., PAREKH, M. N., Mulwani, N., et al. (2026) · doi:10.5005/jodec-11035-0010 · Cited by 1
Tkaczyk, F. M. (2026) · Reports — Medical Cases Images and Videos · doi:10.3390/reports9020142 · Cited by 1
Yokote, K., Yamauchi, T., Fukushima, Y., Takatsuka, Y., Kato, M., Yan, S., Inoue, T., Borowska, L., Brueckmann, M., Ogawa, W., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70862 · Cited by 1
de Oliveira, G. R., Gonçalves, S. R. S., Oliveira, L. R., Guimarães, M. M. C., Nobre, L. B., & Tourinho, L. D. O. S. (2026) · Revista fisio&terapia. · doi:10.69849/v83xr454 · Cited by 1
Trends in Diagnosing Obesity: The CALOR Study
Horn, D. B., Lesén, E., Gray, C. M., Bjursell, M. K., & Waki, H. (2026) · Obesity · doi:10.1002/oby.70264 · Cited by 2
“Obesity is a complex, multifactorial disease characterized by abnormal or excessive accumulation of body fat [1].”
InfluentialYe, H.-L., Wang, Y.-N., Li, G.-A., Jin, X.-H., Li, Y., & Jin, Y.-H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1910505 · Cited by 2
“However, accumulating evidence indicates that they are biologically intertwined through shared metabolic, in fl ammatory, neurohormonal, and hemodynamic mechanisms (8 – 13).”
Pharmacomicrobiomics in metabolic syndrome and type 2 diabetes: the microbiome–drug–host triad
Strilić, D., Stanimirov, B., Pavlović, N., Lazarević, S., Mikov, M., Stanivukovic, T., & Đanić, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1831882 · Cited by 1
Glycemic Outcomes Associated With GLP-1 Receptor Agonist Shortages in Type 2 Diabetes
Fu, Z., Adelman, M., & Garlock, J. (2026) · PRiMER · doi:10.22454/primer.2026.826203 · Cited by 1
Rasool, Z. K., Shah, R., Batool, A. E. Z., Shah, R., Khachatryan, M., Bhardwaj, S., Ali, A., Atta, M., Bakthavatchalam, P., Khawar, M. M. H., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1903335 · Cited by 1
Chaturvedi, R., Singh, K., Chakole, R., Yadav, B. K., Dhameliya, J., & Joshi, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1969433 · Cited by 2
Al-Fayyadh, M. S. M., Ismael, K. H., & AL-Sa’ady, A. J. R. (2023) · University of Thi-Qar Journal of Science · doi:10.32792/utq/utjsci/v10i2.1087 · Cited by 1
Case Study: The Weighty Issue of Treatment Options for Obese Dialysis Patients
de Waal, D., Onuigbo, M. A. C., & Golper, T. A. (2024) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2024.04.004 · Cited by 1
A Focus on the Pharmacotherapy of Obesity
Garvey, W. T. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0006 · Cited by 1
Home, P. D., Lauand, F., Djaballah, K., Li, X., Hafidh, K., Mehta, R., Faraoun, K., Anaforoğlu, İ., Serafini, P. R., & Pourrahmat, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16360 · Cited by 1
Shao, K., Lei, H., Zhu, J., Chen, X., Sina, Y., & Yao, R. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1870603
Brain ischemia and cerebrovascular pathology: possibilities of neurometabolic pharmacotherapy
Бурчинский, С. Г. (2016) · Family Medicine · doi:10.30841/2307-5112.1(63).2016.102302
Novedades en los Standards of Care in Diabetes 2023
Hernández, C. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.2023.1.art1
Bypass ou Sleeve: considerações quanto à escolha do método de cirurgia bariátrica
Silveira, H. F., Pelegrini, J. P. D. A., & Bianchini, M. P. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv8n4-274
Vosburg, R. W. (2025) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.04.465
González‐Vidal, T., Rivas‐Otero, D., Lambert, C., Ares, J., Delgado, E., & Torre, E. L. M. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501577 · Cited by 2
Temporal Modeling and Forecasting of Blood Glucose Dynamics in Individuals With Diabetes Mellitus
Ruff, M. (2025) · PDXScholar (Portland State University) · doi:10.15760/honors.1668
Appiah, C. A., Wugah, H., Carboo, J. A., Amoako, M., Wiafe, M. A., & Hayford, F. E. A. (2025) · Obesities · doi:10.3390/obesities5030056
Kerbage, A., Brunaldi, V., Annan, K. A., Mrad, R., Chandrasekhara, V., Pearson, R. K., Gleeson, F. C., Bofill-García, A., Majumder, S., Law, R. J., et al. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08167-y
The application of low-carb diet in diabetes treatment
Yuchen, H., & Yin, J. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0020
Torrieri, R. (2025) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/183074 · Cited by 1
Chen, L. L., Ludin, A. F. M., Manaf, Z. A., Tohit, N. M., & Shahar, S. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i8.104371 · Cited by 1
Ponce, N. R. P., Paola, S. S. D., Lorena, R. P. D., & Kirina, P. P. N. (2025) · Revista Veritas de Difusão Cientifica. · doi:10.61616/rvdc.v6i2.820
Pérez-López, P., González-Gutiérrez, J., Asensio, L., Jáuregui, O. I., Primo, D., Bachiller, B. R., Andrés, E. L., de Luis, D. A., & Gómez, J. J. L. (2025) · Diabetology · doi:10.3390/diabetology6100108
Relationships between Body Composition and Exercise Capacity in Obese Women
Guedjati, M. R., Taibi, A. D., & MAAKOUF, S. (2025) · International Journal of Kinanthropometry · doi:10.34256/ijk2524
Revolución metabólica: redefiniendo la endocrinología con nuevas terapias basadas en incretinas
Hernández, A. R., Araujo, J. E. G., Castillo, J. F. D., Martínez, M. E. A., Cohen, N. E. Z., Navarro, A. F. U., Chavez, M. A. N., & Morales, A. L. L. (2025) · Star of Sciences Multidisciplinary Journal · doi:10.63969/tg610p62
Boye, K. S., Neff, L. M., Perez‐Nieves, M., Lage, M. J., & Chivukula, K. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70226
“The relatively low and declining use of MBS among adults with T2D, along with the increased rates of post-period medical events and the higher costs associated with procedure, suggest that there may be advantages to alternative, less invasive therapies that address both T2D and obesity.”
Patti, M., Aleppo, G., Kruger, D. F., Levy, C. J., Bushman, J. S., Umpierrez, G. E., Galindo, R. J., Forlenza, G. P., Carlson, A. L., & McGill, J. B. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251396120
Self-citationQuinaglia, T., Silva, G., Matos‐Souza, J. R., Coelho‐Filho, O. R., Nadruz, W., & Sposito, A. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01368-x
Schmiedel, O., Ivey, M. K., Karunasinghe, N., & Murphy, R. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100240
Niraparib induces hyperglycemia in ovarian cancer patients: a preliminary pilot study
Lewandowski, K., Stanisławiak‐Rudowicz, J., Szałek, E., Wolc, A., & Karbownik, A. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00811-9
“These factors also increase the risk of diabetes mellitus (DM) [ 5], which is itself a significant risk factor for OC in women and negatively affects survival and prognosis.”
Isaksson, L., & Roosmann, E. (2025) · Sophiahemmet University Library (Sophiahemmet University)
Neue Kriterien zur Definition und Diagnostik der Adipositas?
Blüher, M. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2606-0632
Chalmers, E. E. (2025) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.10.002
Clarifying the Burden of Obesity in Youth: Measurement Choices—Reply
Chetty, A. K., Chen, A. S., & Nugent, J. T. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.5331
Nuevo algoritmo de redGDPS 2026: de la glucemia al paciente
Soidán, F. J. G., Menéndez, S. A., Lachica, L. Á., Pato, Ó. B., Pradas, N. C., Teixidó, C. H., Vela, N. S., Mera-Gallego, I., & Carretero-Anibarro, E. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.4.art2 · Cited by 1
Pharmacologic glycemic management of type 2 diabetes
Mourelatou, N. G., & Rebelos, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00284-3
COMPARACIÓN DE RESULTADOS CLÍNICOS ENTRE GASTRECTOMÍA EN MANGA Y EL BYPASS GÁSTRICO
Tubon, B. S. S., & Ramos, B. D. C. (2026) · Tesla Revista Científica · doi:10.55204/trc.v5i2.e567
Wei, B., Gao, T., & Liu, Q. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1721267
Jawamis, A., Al-Domi, H. A., & Sarayreh, N. A. (2026) · Nutrition · doi:10.1016/j.nut.2026.113119
Tong, J., Li, N., Hu, F., & Yue, Y. (2026) · European journal of medical research · doi:10.1186/s40001-026-03986-w
“Current evidence and clinical guidelines [34] predominantly indicate that GLP-1 receptor agonists may have superior weight-loss efficacy compared to SGLT-2 inhibitors.”
Management of type 2 diabetes mellitus in overweight patients: an updated review
Jargin, S. V. (2026) · Лечащий врач · doi:10.51793/os.2026.29.2.005
Wu, Y., Wang, Z., Tuersun, A., Yu, Q., Zhong, Y., Ali, S. S. A., Liu, H., Hu, X., Zhang, Y., Pang, L., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04705-2 · Cited by 1
“First, studies with a high risk of bias (Study 7, 8, 18, and 48) were removed.”
InfluentialYang, Z., Wang, J., & Zhang, X. (2026) · Endocrine · doi:10.1007/s12020-025-04501-7
“Obesity and the accumulation of visceral fat are significant contributors to the development of diabetes mellitus [2–5 , 21 ].”
Rosales, A. S. R. (2026) · Universidad Peruana Cayetano Heredia Institutional Repository
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., Garg, R., Khunti, K., Kushner, R. F., Lal, R., Lingvay, I., Matfin, G., Pandya, N., Pekas, E. J., Pilla, S. J., Polsky, S., Segal, A. R., Seley, J. J., Stanton, R. C., & Bannuru, R. R.
- ORCID
- ElSayed, Nuha A.
- McCoy, Rozalina G.
- Aleppo, Grazia
- Balapattabi, Kirthikaa
- Beverly, Elizabeth A.
- Briggs Early, Kathaleen
- Bruemmer, Dennis
- Echouffo-Tcheugui, Justin B.
- Ekhlaspour, Laya
- Garg, Rajesh
- Khunti, Kamlesh
- Kushner, Robert F.
- Lal, Rayhan
- Lingvay, Ildiko
- Pandya, Naushira
- Pekas, Elizabeth J.
- Pilla, Scott J.
- Polsky, Sarit
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Bannuru, Raveendhara R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2024-12-09
- Volume
- 48
- Issue
- Supplement_1
- Pages
- S167-S180
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC11635032
- OpenAlex
- W4405187634
- Cited by
- 236
- References
- 157
- Citations by year
- 2026: 102 · 2025: 119 · 2024: 9
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, weight management, type 2 diabetes, diabetes prevention, diabetes treatment, clinical guidelines
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Obesity, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.